4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) posted its quarterly earnings data on Friday. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Up 1.1 %

Shares of 4D Molecular Therapeutics stock opened at $4.53 on Friday. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25. The company has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. The company’s 50 day moving average is $5.22 and its 200 day moving average is $8.64.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, February 19th. Bank of America decreased their target price on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, February 10th. Morgan Stanley decreased their target price on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Finally, Royal Bank of Canada decreased their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.